# SYMPHONY-2 (NCT04762160)

> SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

No report yet. It can be ordered.

- Drugs tested: tazemetostat plus rituximab
- Indication: relapsed/refractory follicular lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04762160
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Epizyme, Inc.
- Conditions: Follicular Lymphoma
- Interventions: Tazemetostat; Rituximab
- Enrollment: 5
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on SYMPHONY-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=symphony-2-nct04762160